Mersana Therapeutics to Present at the Oppenheimer & Co. 26th Annual Healthcare Conference

December 1, 2015

CAMBRIDGE, Mass., Dec. 1, 2015 -- Mersana Therapeutics, Inc. today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Oppenheimer & Co. 26th Annual Healthcare Conference at The Westin New York Grand Central in New York City on Tuesday, December 8, 2015, at 9:45 a.m. EST.

About Mersana Therapeutics                                         

Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.

Media Contact
6 Degrees
Tony Plohoros
tplohoros@6degreespr.com
(908) 591-2839

Investors Contact
Stern Investor Relations, Inc.
Jesse Baumgartner
Jesse@sternir.com
(212) 362-1200